Theratechnologies Announces Agreement in Principle with Mara

- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024 - Minimum Liquidity Covenant to Decrease Over Time to a Minimum of US$15 million

Related Keywords

Toronto , Ontario , Canada , United States , Montreal , Quebec , Julie Schneiderman , Philippe Dubuc , Toronto Stock Exchange , Theratechnologies Inc , Communications Corporate Affairs , Company Auditors , Drug Administration , Minimum Liquidity Covenant , Not Approved , Liquidity Covenant , Decrease Over Time , Targeted Adjusted , Going Concern Note , Annual Report , Marathon Asset Management , Loan Facility , United States Food , Forward Looking Statements , Looking Statements , Annual Information Form , Vice President , Chief Financial Officer ,